(Z)-beta-Farnesene is the cis isomer of beta-farnesene, an acyclic sesquiterpene that appears in a narrower slice of the AromaForge archive than the better-studied (E)-isomer. The strongest live evidence for this exact isomer supports identity, odor relevance, and occurrence in selected essential-oil and food-aroma studies, including work that flagged cis-beta-farnesene as a key aroma compound in Changpo. Constituent-specific human safety and mechanism data remain sparse, so this record is best framed as a chemistry and aroma marker with honest evidence gaps.
Chemical identity and composition
NIST and PubChem align on the cis or Z isomer identity under CAS 28973-97-9 and formula C15H24. Good Scents lists the material as a flavor and fragrance ingredient. In the local archive, this exact ID is used in chaste tree berry oil, where public composition summaries place (Z)-beta-farnesene among supporting sesquiterpenes rather than as the dominant component.
Aroma and practical use
- Use the recorded green, woody, herbal, fruity, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A Journal of Agricultural and Food Chemistry aroma-evaluation study reported that cis-beta-farnesene was a key aroma compound in Changpo, supporting a direct odor-impact role for this isomer rather than only a compositional listing.
This is one of the strongest exact-isomer findings located in this pass because it links the compound to sensory relevance, not just identity.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2010 chamomile essential-oil paper reported cis-beta-farnesene at 7.12% in the tested Matricaria chamomilla flower oil while evaluating the oil's effect on fungal growth.
This supports real occurrence in aromatic plant material, but the biological activity belongs to the whole oil rather than isolated (Z)-beta-farnesene.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A Food and Chemical Toxicology abstract on Turkish Vitex agnus-castus fruit oil listed (Z)-beta-farnesene at 5.40%, matching the archive's use of this constituent in chaste tree berry context.
This is an occurrence finding that supports local archive relevance more than mechanism or safety.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human clinical safety study, IFRA limit, or RIFM dossier was verified for isolated (Z)-beta-farnesene in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
As a highly unsaturated sesquiterpene hydrocarbon, (Z)-beta-farnesene should be treated as oxidation-prone during storage and not represented as a clinically characterized stand-alone wellness ingredient.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No isolated (Z)-beta-farnesene human clinical or constituent-specific toxicology literature was verified in this pass.
- The exact-isomer literature is thinner than for (E)-beta-farnesene and is weighted toward aroma chemistry or occurrence reporting.
- No strong public source in this pass tied isolated (Z)-beta-farnesene to a clearly replicated biological mechanism.
- No IFRA Standard, Tisserand & Young dermal maximum, or CAS-specific RIFM fragrance ingredient safety assessment for (Z)-beta-farnesene (28973-97-9) was located in two targeted searches; the previous 25% dermal_limit_pct placeholder had no traceable citation and has been removed.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.